Publications
The Oxtend TM-01 study: Debio 4126, a new 12-week octreotide formulation, provides maintenance of disease control in patients with acromegaly…
Debio 0123, a highly selective WEE1 inhibitor in adult patients with advanced solid tumors: a phase 1 dose escalation and…
Debio 0123, a highly selective WEE1 inhibitor, in combination with carboplatin (C) and etoposide (E), in patients with recurrent small…
The WEE1 inhibitor Debio 0123 is synergistic with the PKMYT1 inhibitor lunresertib in preclinical models of ovarian and breast cancer
Debio 1562M, a 2nd Generation ADC Targeting CD37, Shows High Potency Against AML and MDS and Safe Toxicological Profile for…
Biology-driven, machine learning-based development of a biomarker to predict response to WEE1 inhibitor Debio 0123
Site-selective template-directed synthesis of antibody Fc conjugates with concomitant ligand release
The First-in-Class Anti-Staphylococcal Antibiotic Afabicin Desphosphono is Not Associated With Clostridioides difficile Infection in an in vitro Human Gut Model